Form 4: Axim Biotechnologies Director Acquires Convertible Note

Robert Cunningham, a director of Axim Biotechnologies, acquired a convertible note worth $35,000, which can be converted into 3,500,000 shares of common stock at $0.01 per share.

Summary

• On March 15, 2024, Robert Cunningham, a director of Axim Biotechnologies, acquired a convertible note with a face value of $35,000.
• The note can be converted into 3,500,000 shares of Axim Biotechnologies' common stock at a conversion price of $0.01 per share.
• Following this transaction, Cunningham directly owns 4,500,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a transaction by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The acquisition of the convertible note by a director may signal confidence in the company's future prospects to shareholders.
• The transaction could potentially impact the company's capital structure if the note is converted into common stock.

Key Dates

Keywords

Convertible Note, Director, Form 4, AXIM, Acquisition, Beneficial Ownership